Potential role of tamoxifen in prevention of breast cancer

Journal of the National Cancer Institute

Volumn 83, Issue 20, 1991, Pages 1450-1459

  Nayfield, Susan G ^a   Karp, Judith E ^a   Ford, Leslie G ^a   Dorr, F Andrew ^a   Kramer, Barnett S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ANIMAL EXPERIMENT; BREAST CANCER; CANCER PREVENTION; CARCINOGENICITY; CHEMOPROPHYLAXIS; EYE TOXICITY; FEMALE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOSIS;

BONE DENSITY; BREAST NEOPLASMS; CARDIOVASCULAR SYSTEM; FEMALE; HUMAN; LIPIDS; RISK FACTORS; TAMOXIFEN;

EID: 0026009860     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.20.1450     Document Type: Article

References (94)

1. Greenwald P: Issues raised by the Women’s Health Trial. J Natl Cancer Inst 80:788–790, 1988
2. Howe GR, Hirohata T, Hjslop TG, et al: Dietary factors and risk of breast cancer Combined analysis of 12 case-control studies. J Natl Cancer Inst 82:561–569, 1990
3. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127–205, 1984
4. Buckley MM, Goa KL: Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37:451–90, 1989
5. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. EndocrRev 11:578–610, 1990
6. Sutherland RL, Reddel RR, Murphy LC, et al: Effects of antiestrogens on cell cycle progression. In Estrogen/Antiestrogen Action and Breast Cancer Therapy (Jordan VC, ed). Madison, Wis: Univ Wise Press, 1986, pp 265–281
7. Knabbe C, Lippman ME, Wakefield LM, et al: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–28, 1987
8. Colletti RB, Roberts JD, Devlin JT, et al: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49:1882–1884, 1989
9. Taylor SG, Gelman RS, Falkson G, et al: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104:455–461, 1986
10. O’Brian CA, Uskamp RM, Solomon DH, et al: Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462–2465, 1985
11. Lam HY: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118:27–32, 1984
12. Luciani L, Oriana S, Spatti G, et al: Hormonal and receptor status in postmenopausal women with endometrial carcinoma before and after treatment with tamoxifen. Tumori 70:189–192, 1984
13. Yasumura T, Akami T, Mjtsuo M, et al: The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer. Jpn J Surg 20:369–375, 1990
14. Ravtxn PM, Fritz NF, Tormey DC, et al: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026–1029, 1988
15. Gordon D, Beastall GH, McArdle CS, et al: The effect of tamoxifen therapy on thyroid function tests. Cancer 58:1422–1425, 1986
16. Jordan VC, Gottardis MM, Robinson SP, et al: Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer. J Steroid Biochem 34:169–176, 1989
17. Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83:492–496, 1991
18. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12:419–424, 1976
19. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239–251, 1980
20. Robinson SP, Mauel DA, Jordan VC: Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 24:1817–1821, 1988
21. Gottardis MM, Jordan VC: The antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-indi)ced rat mammary carcinoma model. Cancer Res 47:4020–4024, 1987
22. Early Breast Cancer Trialists’ Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681–1692, 1988
23. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2:171–175, 1987
24. Prior P, Waterhouse JA: Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. Br J Cancer 37:620–634, 1978
25. Harris RE, Lynch HT, Guirois HA: Familial breast cancer: Risk to the contralateral breast. J Natl Cancer Inst 60:955–960, 1978
26. Novaldex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57:608–611, 1988
27. Rutqvist LE, Cedermark B, Glas U, et al: The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res Treat 10:255–266, 1987
28. Palshof T, Mourisden HT, Daehnfeldt JL, et al: Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. Rev Endocrine-Related Cancer suppl 17:43–50, 1985
29. Pritchard KI, Meakin JW, Boyd NF, et al: Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer: An update. In Adjuvant Therapy of Cancer V (Salmon SE, ed). New York: Grune and Stranon, 1987, pp 391-400
30. Cummings FJ, Gray R, Davis TE, et al: Tamoxifen versus placebo: Double-blind adjuvant trial in elderly women with stage II breast cancer. In Proceedings of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. Bethesda, Md:NIH, 1986, pp 119–123
31. Fisher B, Costanttno J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484, 1989
32. CRC Adjuvant Breast Trial Working Party: Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57:604–607, 1988
33. RÖssner S, Walloren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339–346, 1984
34. Bagdade JD, Wolter J, Subbaiah PV, et al: Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab70:1132–1135, 1990
35. Brunino PF, Bonfrer JM, Hart AA, et al: Tamoxifen, serum lipoproteins and cardiovascular risk. BrJ Cancer 58:497–499, 1988
36. Bertelli G, Pronzato P, Amoroso D, et al: Adjuvant tamoxifen in primary breast cancer Influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12:307–310, 1988
37. Ingram D: Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer. Aust N Z J Surg 60:673–675, 1990
38. Love RR, Newcomb PA, Weibe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327–1332, 1990
39. Prentice RL: Tamoxifen as a potential preventive agent in healthy postmenopausal women. J Natl Cancer Inst 82:1310–1311, 1990
40. Stewart HJ: The Scottish Adjuvant tamoxifen trials. Presented at the NIH Consensus Development Conference on Early Stage Breast Cancer, Bethesda, Md, June 18–21, 1990
41. Barrett-Connor E, Bush TL: Estrogen replacement and coronary heart disease. Cardiovasc Clin 19:159–172, 1989
42. Steinberg KK, Thacker SB, Smith SJ, et al: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985–1990, 1991
43. Stewart PJ, Stern PH: Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro. Endocrinology 118:125–131, 1986
44. Jordan VC, Phelps E, Lindgren JU: Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31–35, 1987
45. Love RR, Mazess RB, Tormey DC, et al: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:279–302, 1988
46. Fornander T, Rutqvist LE, Sjöberg HE, et al: Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019–1024, 1990
47. Gotfredsen A, Chrktiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53:853–857, 1984
48. Powles TJ, Hardy JR, Ashley SE, et al: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. BrJ Cancer 60:126–131, 1989
49. Fentiman IS, Caleffi M, Rodin A, et al: Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 60:262–264, 1989
50. Wolter J, Ryan WG, Subbaiah V, et al: Apparent beneficial effects of tamoxifen on serum lipoprotein subtractions and bone mineral content in patients with breast cancer. Proc Am Soc Clin Oncol 7:10 (A-34), 1988
51. Turken S, Sous E, Seldin D, et al: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086–1088, 1989
52. Hui SL, Slemenda CW, Johnston CC Jr: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809, 1988
53. Love RR: Tamoxifen therapy in primary breast cancer Biology, efficacy, and side effects. J Clin Oncol 7:803–815, 1989
54. Ferrazzi E, Carth G, Mattarazzo R, et al: Oestrogen-like effect of tamoxifen on vaginal epithelium. Br Med J 1:1351–1352, 1977
55. Estevez RA, Breier S, Koutar M: Estudio preliminar con tamoxifen en cancer avanzado de mama. Int UICC Cancer Congress (Buenos Aires) 2:78–79, 1978
56. Novaldex Adjuvant Trial Organisation: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Novaldex Adjuvant Trial Organisation. Lancet 1:836–840, 1985
57. McKeown CA, Swartz M, Blom J, et al: Tamoxifen retinopathy. Br J Ophthalmol 65:177–179, 1981
58. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM: Tamoxifen retinopathy. A clinicopathologic report Ophthalmology 88:89–93, 1981
59. Vinding T, Nielsen NV: Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol 61:45–50, 1983
60. Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 62:315–320, 1978
61. Pugesgaard T, Von Eyben FE: Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 58:383–386, 1986
62. Ashford AR, Donev I, Tiwari RP, et al: Reversible ocular toxicity related to tamoxifen therapy. Cancer 61:33–35, 1988
63. Griffiths MF: Tamoxifen retinopathy at low dosage. Am J Ophthalmol 15:185–186, 1987
64. Gerner EW: Ocular toxicity of tamoxifen. Ann Ophthalmol 21:420–423, 1989
65. Beck M, Mills PV: Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 63:1833–1834, 1979
66. Longstaff S, Sigurdsson H, O’Keeffe M, et al: A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breastcarcinoma. Eur J Cancer Clin Oncol 25:1805–1808, 1989
67. ICI Pharmaceuticals Group: Data presented at the Food and Drug Administration Oncology Drugs Advisory Committee Meeting, Bethesda, Md, June 29, 1990
68. Nevasaari K, Heikkinen M, Taskinen PJ: Tamoxifen and thrombosis. Lancet 2:946–947, 1978
69. Jacquot C, Craterol R, Bariety J, et al: DES versus tamoxifen in advanced breast cancer. N Engl J Med 304:1041–1043, 1981
70. Dahan R, Espie M, Mignot L, et al: Tamoxifen and arterial thrombosis. Lancet 1:638, 1985
71. Enck RE, Rios CN: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53:2607–2609, 1984
72. Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res 47:4517–519, 1987
73. Caleffi M, Fentiman IS, Clark GM, et al: Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 119:335–339, 1988
74. Healey B, Tormey DC, Gray R, et al Arterial and venous thrombotic events in ECOG adjuvant breast cancer trials. Proc Am Soc Clin Oncol 6:54 (A-208), 1987
75. Robinson SP, Jordon VC: Metabolism of steroid-modifying anticancer agents. Pharmacol Ther 36:41–103, 1988
76. Satyaswaroop PG, Zajno RJ, Mortel R: Estrogen-like effects of tamoxifen on human endomerrial carcinoma transplanted into nude mice. Cancer Res 44:4006–4010, 1984
77. Boccardo F, Guarneri D, Rubagotti A, et al: Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 70:61–68, 1984
78. Killackey MA, Hakes TB, Pierce VK, et al: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237–238, 1985
79. Hardell L: Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 2:563, 1988
80. Mathew A, Chabon AB, Kabakow B, et al: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. N Y State J Med 90:207–208, 1990
81. Malfetano JH: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 39:82–84, 1990
82. Atlante G, Pozzi M, Vincenzoni C, et al: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37:378–380, 1990
83. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117–120, 1989
84. Adami HO, Persson I, Hoover R, et al: Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44:833–839, 1989
85. Franca villa A, Poumeno L, DiLeo A, et al: The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 9:614–620, 1989
86. Yager JD, Roebuck BD, Paluszcyk TL, et al: Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis 7:2007–2014, 1986
87. Kohigashi K, Fukuda Y, Imura H: Inhibitory effect of tamoxifen on diethylstilbestrol-promoted hepatic tumongenesis in male rats and its possible mechanism of action. Jpn J Cancer Res 79:1335–1339, 1988
88. Mishkin SY, Farber E, Ho R, et al: Tamoxifen alone or in combination with estradiol-17 beta inhibits the growth and malignant transformation of hepatic hyperplastic nodules. Eur J Cancer Clin Oncol 21:615–623, 1985
89. Ghia M, Mereto E: Induction and promotion of gamma-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett 46:195–202, 1989
90. Eisenfeld AJ, Aten RF: Estrogen receptors and androgen receptors in the mammalian liver. J Steroid Biochem 27:1109–1118, 1987
91. Dawson DA, Thompson GB: Breast cancer risk factors and screening: United States, 1987. Vital Health Stat [10] (172):l–60, 1990
92. Gail MH, Brinton LA, Byar DP, et al Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886, 1989
93. Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancer risk. J Natl Cancer Inst 48:605–613, 1972
94. Dupont WD, Page DL: Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 125:769–779, 1987